Dermatology Continuing Medical Education

Episodes 1-15 of 28

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  0

  

  RestartResume

  What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?

  What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  1

  

  RestartResume

  Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?

  Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?

  2.25 program credits

• • 

    

    Brian Gastman, MD

    Peer

  • 

    

    Michael T. Tetzlaff, MD, PhD

    Peer

  2

  

  RestartResume

  Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?

  Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  1

  

  RestartResume

  What Are the Data Supporting Neoadjuvant Therapy in Melanoma?

  What Are the Data Supporting Neoadjuvant Therapy in Melanoma?

  2.25 program credits

• • 

    

    Brian Gastman, MD

    Peer

  1

  

  RestartResume

  Preoperative Concerns Regarding Neoadjuvant Therapy and Delays in Surgery

  Preoperative Concerns Regarding Neoadjuvant Therapy and Delays in Surgery

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  2

  

  RestartResume

  What Are the Data Supporting Adjuvant Therapy in Melanoma?

  What Are the Data Supporting Adjuvant Therapy in Melanoma?

  2.25 program credits

• • 

    

    Michael T. Tetzlaff, MD, PhD

    Peer

  0

  

  RestartResume

  Surrogate Endpoints for ICIs in Early-Stage Melanoma: Does an MPR Reliably Predict Patient Outcomes?

  Surrogate Endpoints for ICIs in Early-Stage Melanoma: Does an MPR Reliably Predict Patient Outcomes?

  2.25 program credits

• • 

    

    Brian Gastman, MD

    Peer

  1

  

  RestartResume

  Who Is Eligible for Neoadjuvant or Adjuvant Immunotherapy?

  Who Is Eligible for Neoadjuvant or Adjuvant Immunotherapy?

  2.25 program credits

• • 

    

    Brian Gastman, MD

    Peer

  0

  

  RestartResume

  Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression?

  Lack of Concordance Between Radiologic and Pathologic Responses in Neoadjuvant ICI Treatment of Melanoma: How Do I Assess Radiologic Progression?

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Brian Gastman, MD

    Peer

  0

  

  RestartResume

  Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?

  Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Brian Gastman, MD

    Peer

  • 

    

    Michael T. Tetzlaff, MD, PhD

    Peer

  1

  

  RestartResume

  Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers

  Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers

  2.25 program credits

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Brian Gastman, MD

    Peer

  • 

    

    Michael T. Tetzlaff, MD, PhD

    Peer

  0

  

  Integrating Immune Checkpoint Therapy Into the Management of Resectable Melanoma

  2.25 credits 12 episodes

• • 

    

    Jeffrey S. Weber, MD, PhD

    Peer

  • 

    

    Brian Gastman, MD

    Peer

  • 

    

    Michael T. Tetzlaff, MD, PhD

    Peer

  0

  

  RestartResume

  Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas

  Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas

  2.25 program credits

• • 

    

    William Mencia, MD, FACEHP, CHCP

    Peer

  • 

    

    Julie Blatt, MD

    Peer

  • 

    

    Taizo Nakano, MD

    Peer

  0

  

  RestartResume

  Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment

  Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment

  0.50 credits

• • 

    

    Jason D. Bloom, MD, FACS

    Peer

  • 

    

    Carolyn I. Jacob, MD, FAAD

    Peer

  9

  

  RestartResume

  Update on Botulinum Toxins for Aesthetic Indications: Duration, Anatomy, and Other Patient-Centric Considerations

  Update on Botulinum Toxins for Aesthetic Indications: Duration, Anatomy, and Other Patient-Centric Considerations

  0.50 credits

• 1
• 2
• Next